^




    Show legend
    Group by Gene:
    Include preclinical:

    Mvasi (bevacizumab biosimilar)
    Aybintio (bevacizumab biosimilar)
    		0
    VEGF-A inhibitor
    Zirabev (bevacizumab biosimilar)
    Bevax (bevacizumab biosimilar)
    Krabeva (bevacizumab biosimilar)
    bevacizumab
    cabozantinib tablet
    		1
    Multi-tyrosine kinase inhibitor
    pazopanib
    cabozantinib capsule
    nivolumab
    pembrolizumab
    		2
    PD1 inhibitor
    dostarlimab
    toripalimab
    PD1 inhibitor
    everolimus
    		3
    mTOR inhibitor
    temsirolimus
    sirolimus
    mTOR inhibitor
    4
    IFNα stimulant, VEGF-A inhibitor
    bevacizumab + pegylated interferon α -2a
    Aybintio (bevacizumab biosimilar) + pegylated interferon α -2a
    5
    VEGFR inhibitor, PD1 inhibitor
    pembrolizumab + axitinib
    6
    PD1 inhibitor, Multi-tyrosine kinase inhibitor
    nivolumab + cabozantinib tablet
    7
    PD1 inhibitor, CTLA4 inhibitor
    nivolumab + ipilimumab
    8
    c-MET inhibitor
    savolitinib
    c-MET inhibitor
    9
    VEGFR inhibitor, PD-L1 inhibitor
    avelumab + axitinib
    10
    VEGF-A inhibitor, EGFR inhibitor
    bevacizumab + erlotinib
    11
    VEGFR inhibitor
    axitinib
    12
    EGFR inhibitor
    erlotinib
    13
    HIF-2α inhibitor
    belzutifan
    PT2385
    14
    ALK inhibitor
    crizotinib
    alectinib
    15
    CD70-targeted CAR-T immunotherapy
    ALLO-316
    atezolizumab
    		16
    PD-L1 inhibitor
    avelumab
    PD-L1 inhibitor
    17
    PARP inhibitor
    olaparib
    18
    FGFR inhibitor
    ABSK091
    19
    CDK4 inhibitor, CDK6 inhibitor
    palbociclib
    20
    PD1 inhibitor, IDO1 inhibitor
    nivolumab + BMS-986205
    pembrolizumab + INCB024360
    21
    VEGFR-2 inhibitor, c-MET inhibitor
    GSK1363089
    22
    HDAC inhibitor, Multi-tyrosine kinase inhibitor
    pazopanib + CG-781
    23
    VEGF-A inhibitor, PI3Kγ inhibitor, Tubulin inhibitor
    bevacizumab + albumin-bound paclitaxel + IPI-549
    24
    mTORC1 inhibitor, mTORC2 inhibitor
    CB-228
    25
    ALK inhibitor, Multi-tyrosine kinase inhibitor
    crizotinib + pazopanib
    26
    VEGFR inhibitor, mTOR inhibitor
    temsirolimus + axitinib
    27
    BRAF inhibitor
    vemurafenib
    28
    VEGFR inhibitor, PDGFR inhibitor, c-KIT inhibitor
    sunitinib
    29
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, c-KIT inhibitor, PDGFR α antagonist
    lenvatinib
    30
    pan-RAF inhibitor, Multi-tyrosine kinase inhibitor
    sorafenib
    31
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PD1 inhibitor, c-KIT inhibitor, PDGFR α antagonist
    pembrolizumab + lenvatinib
    32
    CD122 agonist, IL-2 stimulant
    aldesleukin
    33
    VEGFR-1 inhibitor, VEGFR-2 inhibitor, VEGFR-3 inhibitor
    tivozanib
    34
    FGFR inhibitor, VEGFR inhibitor, RET inhibitor, mTOR inhibitor, c-KIT inhibitor, PDGFR α antagonist
    everolimus + lenvatinib
    35
    PD-L1 inhibitor, VEGF-A inhibitor, PI3Kγ inhibitor
    bevacizumab + atezolizumab + IPI-549
    36
    TIM-1-targeted antibody-drug conjugate, Microtubule inhibitor
    CDX-014
    37
    PD-L1 inhibitor, VEGF-A inhibitor
    bevacizumab + atezolizumab
    38
    PRC2 inhibitor
    MRTX2219
    39
    ATR inhibitor
    M6620
    40
    UCHL1 inhibitor, Androgen receptor inhibitor
    enzalutamide capsule + 6RK73
    41
    RAC1 inhibitor
    NSC23766
    42
    CYP17A1 inhibitor
    abiraterone acetate
    43
    pan-RAF inhibitor, Hyaluronic acid synthase inhibitor, Multi-tyrosine kinase inhibitor
    sorafenib + 4-methylumbelliferone
    44
    DNA synthesis inhibitor
    cisplatin
    45
    TGM2 inhibitor
    MD102
    46
    MEK2 inhibitor, MEK1 inhibitor
    U0126
    47
    Topoisomerase II inhibitor
    doxorubicin hydrochloride
    48
    pan-RAF inhibitor, VEGFR inhibitor, PDGFR inhibitor, Multi-tyrosine kinase inhibitor, c-KIT inhibitor
    sorafenib + sunitinib
    49
    VEGFR inhibitor, PDGFR inhibitor, Multi-tyrosine kinase inhibitor, c-KIT inhibitor
    sunitinib + pazopanib
    50
    PD-L1 inhibitor, VEGF-A inhibitor, PDGFR inhibitor
    avelumab + CLS-AX
    51
    Immunotherapy
    Immunotherapy
    52
    Glutamate inhibitor
    Glutamate inhibitor
    53
    VEGF inhibitor
    VEGF inhibitor
    54
    Tyrosine kinase inhibitor
    Tyrosine kinase inhibitor
    No biomarker
    MET amplification
    MET mutation
    MET fusion
    PD-L1 expression
    PD-L1 overexpression
    PD-L1 underexpression
    PBRM1 mutation
    PBRM1 overexpression
    PBRM1 deletion
    PBRM1 negative
    PBRM1 underexpression
    KDR rs2071559
    KDR C482R
    KDR expression
    MTOR mutation
    FLT1 rs9554320
    MTOR Q2223K
    FLT1 expression
    ROBO3 mutation
    AXL-L
    ARID1A mutation
    AXL overexpression
    AXL expression
    PD-1 expression
    ALK rearrangement
    VHL mutation
    HGF expression
    HGF-L
    TSC1 deletion
    TSC2 H1620R + TSC2 Y1650C
    HMOX1 expression
    TSC2 mutation
    TSC1 mutation
    HMOX1-L
    VHL deletion
    HGF-H
    PD-1-H
    VHL promoter methylation
    IL6-L
    MSI-H/dMMR
    BRCA1 mutation
    BRCA2 mutation
    KIM1 expression
    FLCN mutation
    TFE3 translocation
    HDAC2 expression
    ERVE-4 expression
    HAVCR2 expression
    SPP1-L
    CXCL8-L
    IL18 expression
    ANGPT2 expression
    TIMP1 expression
    CSF1 expression
    VEGFA expression
    CXCL9 expression
    IL18BP expression
    SYNE1 mutation
    CDKN2A mutation
    CEACAM1 overexpression
    CXCL10 overexpression
    CA9 expression
    CD31 expression
    GNAQ mutation
    IKZF2-L
    KDM5C mutation
    PDGFRA expression
    CD8 expression
    HIF1A expression
    LRP1B mutation
    ELTD1 expression
    BAP1 negative
    IL6R L
    IL6ST-H
    TFEB translocation
    EWSR1-POU5F1 fusion
    KMT2C mutation
    LDH elevation
    CTLA4 promoter hypomethylation
    NANOGNB mutation
    PARP1 underexpression + PBRM1 mutation
    PTTG1 overexpression
    TNFRSF9 elevation
    PD-L1 expression + CD14 positive
    LAG3 positive + CD4 positive
    TNFRSF9 positive + CD8 positive
    TNFRSF9 positive + CD4 positive
    NF2 mutation
    FH mutation
    FOLH1 overexpression
    KHDRBS1 overexpression
    PBRM1 mutation + SETD2 mutation
    TERT promoter mutation
    BRAF mutation
    miR138 underexpression + miR497 overexpression
    SETD2 mutation + TP53 mutation
    FLCN deletion
    BAP1 mutation
    IL6-H
    CXCL10-H
    TERT overexpression
    IL6 elevation
    BAP1 deletion
    VEGFA-H
    SETD2 mutation
    CXCL8 elevation
    VEGFA elevation
    CDKN2A deletion
    KIM1 elevation
    Tregs-H
    DDR
    T-cell-inflamed GEP signature
    IFNG gene signature overexpression
    Chr del(9)(p21.3)
    CXCR4 overexpression
    PAI1-H
    TGM2 overexpression
    CXCL12-H
    HLA-A*03
    PRCC-TFE3 fusion
    HAS3 expression
    TP53 expression
    DAPK1 underexpression
    EPAS1 overexpression
    MCAM overexpression
    PLK1 overexpression
    miR-155 underexpression
    FGFR1 overexpression
    SMARCA4 mutation
    LAG3 expression
    KDM6A mutation
    CCL4 elevation
    CXCL11-H
    AR-V7 positive
    DDX39B overexpression
    AXL overexpression + PD-L1 expression
    CCNE1 amplification
    TP53 mutation
    CTBP1 deletion
    CXCL13 elevation
    TNFSF13B elevation
    TMB-H
    CD44 expression
    CD44 positive
    ACRBP amplification
    GNAS amplification
    LRP10 deletion
    IL7 elevation
    SULT1A3 amplification
    UGT1A9 expression
    ADCYAP1 deletion
    PTEN deletion
    NT5E overexpression
    MTA2 overexpression
    IL13RA2 overexpression